BOSTON — The three years since Cerebral’s launch have been a whirlwind. With a promise to expand access to mental health care and medications online, the company landed a stunning $462 million in funding by the end of 2021. But by summer 2022, the company was under intense pressure as its prescribing and business practices drew scrutiny from federal agencies and prosecutors.
As Cerebral navigates the fallout of those investigations and a fast-changing telehealth landscape, its CEO stressed that Cerebral is working to improve the quality of mental health care.
“I’m really confident about the clinical side of what we have been doing and we are doing going forward,” David Mou, a physician who took over as CEO of the embattled company in May, said Wednesday at the STAT Summit.
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect